FDA OKs Evofem contraceptive Phexxi
May 22, 2020 12:11 PM ET|About: Evofem Biosciences, Inc. (EVFM)|By: Douglas W. House, SA News Editor
The FDA has approved Evofem Biosciences' (EVFM -2.5%) Phexxi (L-lactic acid, citric acid, potassium bitartrate) Vaginal Gel 1.8%/1%/0.4%, a contraceptive that works by maintaining an acidic environment in the vagina that is inhospitable to sperm.
The company refiled its U.S. application in December 2019 after receiving a CRL in 2016 in response to original submission.
Shares, while still in the red, are moving up from intraday lows.
See all stocks on the move »
Always consult an Investment Professional, my posts are my own opinions, and not for investing decisions
